Our Technology
By locking peptides into their bioactive α-helical conformation through a site-specific chemical brace, we aim to advance innovative medicines for unmet aggressive pathologies by specifically targeting previously undruggable targets
Peptide Technologies Targeting Protein-Protein Interactions
Our technology is centered on constraining short chains of amino acids — polypeptides — in a specific folded shape known as an α-helical conformation, which confers upon them, unique drug-like properties including enhanced membrane permeability and stability
Our Pipeline
SPM001
Therapeutic modality Stapled Peptide
Target Myddosome complex (Myd88)
Indications Myd88 mutated cancers
Inflammatory disorders
Inflammatory disorders
Discovery
Pre-Clinical
Clinical
SPM002
Therapeutic modality PROTAC Peptide
Target Undisclosed
Indications Undisclosed
Discovery
Pre-Clinical
Clinical